Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
26 results
D1.227 - Nanobody-based anti-FcεRI antibodies for therapeutic targeting of the IgE-FcεRI complex
D1.228 - Mitochondrial Epigenetic Programming: A Unifying Mechanism Linking Environmental Stress, Epithelial Barrier Dysfunction, and Allergy
D1.229 - Real-life observational study on allergen-specific Immunotherapy with double-polymerized allergoids (Modigoid Cup a1) in patients allergic to Cupressus Arizonica pollen
D1.218 - Effects of butyrylated high amylose maize starch (HAMSB) as an adjuvant for oral immunotherapy
D1.219 - Efficacy and Safety of 300 IR Liquid Sublingual Immunotherapy in Allergic Asthma: A Systematic Review and Meta-analysis of Randomised Controlled Trials
D1.221 - Identification of IgE epitopes of major ragweed pollen allergens (Amb a 1 and Amb a 11)
D1.222 - Production of Bet v 1-specific IgG antibodies in mice immunized with the recombinant vaccine ABP-Vax
D1.223 - TNFR2 regulates early PD-L1/PD-L2 induction and Th1-associated cytokine responses during the early events of Allergen-Specific Immunotherapy (AIT) in a preclinical model
D1.224 - Rational Design of a T-Cell Epitope-Based Chimeric Allergen from Dermatophagoides pteronyssinus Toward Precision Immunotherapy
D1.225 - Long-term adherence to seasonal allergen immunotherapy: a 3-year (22/23-24/25) retrospective study on 174 patients
D1.226 - Allergen Immunotherapy Preferences by Patient in Some Arabic countries: The CHOICE-Middle East Study
D1.230 - Efficacy and Safety of Hymenoptera Venom Immunotherapy in a Patient with Systemic Mastocytosis
D1.231 - Endotype-Guided Management of Allergic Asthma in a Pediatric Athlete: Impact of Sublingual Immunotherapy
D3.213 - Sustained effectiveness of the 300 IR house dust mite sublingual tablet over 2 treatment years in a real-world data setting – results of a non-interventional study
D3.198 - Challenges of using clinical scores as primary endpoints in allergology trials
D3.199 - Severe systemic allergic reaction following violation of elimination diet in a patient with sensitization despite achieved remission on allergen-specific immunotherapy
D3.200 - Broad profile of olive pollen sensitisation as a key factor in immunotherapy failure
D3.201 - Subcutaneous immunotherapy with a depigmented cat allergoid is safe in patients with cat allergy and beneficial for mental health in adolescents
D3.202 - Characterising relevant major allergens beyond modification: from allergen to allergoid
D3.203 - Characterisation of relevant allergens in grass pollen extracts
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download